LFCR (Lifecore Biomedical) LT-Debt-to-Total-Asset: 0.66 (As of Mar. 2026)

What is Lifecore Biomedical LT-Debt-to-Total-Asset?

Lifecore Biomedical LFCR +2.41% 55 LT-Debt-to-Total-Asset is 0.66 as of Mar. 2026. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.52 (Modestly Undervalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lifecore Biomedical's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.66.

Lifecore Biomedical's long-term debt to total assets ratio increased from Feb. 2025 (0.53) to Mar. 2026 (0.66). It may suggest that Lifecore Biomedical is progressively becoming more dependent on debt to grow their business.

Lifecore Biomedical (NAS:LFCR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lifecore Biomedical LT-Debt-to-Total-Asset Related Terms

Lifecore Biomedical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical LT-Debt-to-Total-Asset Chart

Lifecore Biomedical Annual Data

Trend

May16

May17

May18

May19

May20

May21

May22

May23

May24

May25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.37

0.03

0.44

0.49

0.53

Lifecore Biomedical Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.53	0.53	0.57	0.61	0.66

55GF Score

Lifecore Biomedical Inc LFCR

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lifecore Biomedical LT-Debt-to-Total-Asset Calculation

Lifecore Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in May. 2025 is calculated as

LT Debt to Total Assets (A: May. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: May. 2025 )	/	Total Assets (A: May. 2025 )
	=	126.999	/	239.342
	=	0.53

Lifecore Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	147.779	/	225.499
	=	0.66

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.66 mean?

Lifecore Biomedical (LFCR) has a LT-Debt-to-Total-Asset of 0.66 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lifecore Biomedical and its competitors.

Is Lifecore Biomedical's LT-Debt-to-Total-Asset too high?

Lifecore Biomedical's current LT-Debt-to-Total-Asset is 0.66. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Lifecore Biomedical's LT-Debt-to-Total-Asset compare to ANIK and DERM?

Lifecore Biomedical's LT-Debt-to-Total-Asset of 0.66 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current LT-Debt-to-Total-Asset is 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lifecore Biomedical stock overvalued right now?

Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $5.09 — trading 21.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.66. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current LT-Debt-to-Total-Asset is 0.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (LFCR) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of $5.09 is trading 21.9% below its estimated GF Value™ of $6.52. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for LFCR:

LT-Debt-to-Total-Asset: 0.66
GF Value™: $6.52 vs. price of $5.09 (21.9% below fair value)
GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lifecore Biomedical Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ANIK DERM ASRT SIGA CPIX AKBA TKNO ORGO INCR CTOR XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges LDE:Germany

Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318

Website https://www.lifecore.com

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

55GF Score

Get the complete analysis for LFCR

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.09

Price

$6.52

GF Value

View LFCR Analysis

See LT-Debt-to-Total-Asset data for all stocks →